Drug intelligence / Profile preview

VU369

Development stage
Unknown
Lead developer
Allgems Healthcare
Modality
Small Molecules
Administration
Oral
01

Overview

VU369 is an oral dietary supplement developed and marketed by Allgems Healthcare. It is formulated with a combination of omega fatty acids, typically including omega-3, omega-6, and omega-9 fatty acids. These essential polyunsaturated and monounsaturated fats are critical for maintaining cell membrane integrity and serve as precursors to signaling molecules that modulate inflammatory responses and lipid metabolism. VU369 is primarily indicated for the support of cardiovascular health and as a general nutritional supplement to maintain healthy lipid levels and support heart and brain function. As a nutraceutical product, it is part of Allgems Healthcare's portfolio of branded generics and health supplements.

Brand names
VU369VU-369VU 369
Other names
omega-3-6-9 fatty acidsomega3-6-9 fatty acidsomega 3-6-9 fatty acidsomega fatty acids
02

Targets

PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)FFAR4 (Free fatty acid receptor 4)

Beyond the preview

Go deeper on VU369.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on VU369.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call